Close

Cambrex Corp. (CBM) to Acquire Privately-Held PharmaCore for ~$25M

Go back to Cambrex Corp. (CBM) to Acquire Privately-Held PharmaCore for ~$25M

Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities

September 26, 2016 6:45 AM EDT

EAST RUTHERFORD, N.J., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has agreed to acquire PharmaCore Inc., a privately-owned company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approximately $25 million. PharmaCore was founded in 1999 and occupies a 35,000 sq. ft. GMP site in High Point, North Carolina, USA.

PharmaCore develops and produces complex APIs and intermediates requiring multi-step synthetic processes in batch... More